The Incidence, Survival, and HPV Impact of Second Primary Cancer following Primary Oropharyngeal Squamous Cell Carcinoma: A 20-Year Retrospective and Population-Based Study.
Male
Female
Humans
Squamous Cell Carcinoma of Head and Neck
Retrospective Studies
Incidence
Oropharyngeal Neoplasms
/ epidemiology
Human Papillomavirus Viruses
Carcinoma, Squamous Cell
/ epidemiology
Papillomavirus Infections
/ complications
Neoplasms, Second Primary
/ epidemiology
Head and Neck Neoplasms
Papillomaviridae
/ genetics
human papillomavirus
oropharyngeal cancer
second primary cancer
squamous cell carcinoma
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
22 12 2022
22 12 2022
Historique:
received:
02
12
2022
revised:
17
12
2022
accepted:
18
12
2022
entrez:
21
1
2023
pubmed:
22
1
2023
medline:
25
1
2023
Statut:
epublish
Résumé
Second primary cancer (SPC) is the second most common cause of death among patients diagnosed with head and neck cancer. This study examined the risk of SPC following oropharyngeal squamous cell carcinoma (OPSCC) and the impact of human papillomavirus (HPV) on survival following SPC. The study was a population-based, retrospective study including all patients diagnosed with OPSCC in eastern Denmark from 2000-2020 who received curative intended treatment. The incidence rate ratio (IRR), age-adjusted incidence rates (AAIR), and hazard ratios (HR) were calculated. A total of 2584 patients with primary OPSCC were included (median follow-up time: 3.1 years), with 317 patients (12.3%) diagnosed with SPC. The risk of SPC was approximately five times the occurrence of cancer in the general population (IRR: 4.96). The median time to SPC after a primary OPSCC was 2.0 years (interquartile range (IQR) = 0.6-4.2 years). HPV-positive (HPV+) patients had a significantly longer median time to SPC, and a significant better survival compared to HPV-negative (HPV-) patients. SPC was most frequently found in lungs, head, and neck (LHN) for HPV- OPSCC patients and lungs followed by gender-specific (prostate, ovaries, or endometrium) for HPV+ OPSCC. There was a significant difference between the two groups when distributed between "within" or "outside" LHN. Patients with SPC outside LHN had a significant better overall survival. This knowledge should be considered during post-treatment surveillance and might guide targeted imaging.
Identifiants
pubmed: 36680074
pii: v15010034
doi: 10.3390/v15010034
pmc: PMC9867066
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Références
Cancer Lett. 2005 Apr 8;220(2):185-95
pubmed: 15766594
Nature. 2015 Jan 29;517(7536):576-82
pubmed: 25631445
Int J Cancer. 2011 Aug 1;129(3):733-41
pubmed: 20878955
Future Oncol. 2020 Feb;16(6):199-207
pubmed: 31967480
Int J Cancer. 2010 Jun 15;126(12):2879-84
pubmed: 19856308
Int J Cancer. 2015 May 1;136(9):2196-203
pubmed: 25283302
JAMA Netw Open. 2018 Sep 7;1(5):e181999
pubmed: 30646145
Cancer Med. 2018 Jan;7(1):87-94
pubmed: 29171183
Cells. 2019 Sep 10;8(9):
pubmed: 31510065
Cancer Causes Control. 2009 Jul;20(5):645-52
pubmed: 19067191
Histopathology. 2012 Feb;60(3):427-36
pubmed: 22211374
Oral Oncol. 2018 Aug;83:127-133
pubmed: 30098768
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Cancer. 2013 May 15;119(10):1832-7
pubmed: 23423883
Cancer. 2014 May 15;120(10):1507-13
pubmed: 24863390
J Otolaryngol Head Neck Surg. 2013 May 29;42:36
pubmed: 23718873
Eur J Cancer. 2017 Jan;70:75-82
pubmed: 27888679
Eur Arch Otorhinolaryngol. 2005 Nov;262(11):905-9
pubmed: 15891925
Oncotarget. 2017 Feb 28;8(9):14416-14427
pubmed: 28122336
Int J Cancer. 2022 Apr 1;150(7):1174-1183
pubmed: 34894151
Int J Cancer. 2011 Jun 15;128(12):2892-7
pubmed: 20725995
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
Eur J Cancer. 2020 Jul;134:52-59
pubmed: 32460181
Int J Cancer. 2016 Dec 1;139(11):2598-605
pubmed: 27537425
Oral Oncol. 2021 Jan;112:105041
pubmed: 33129057
Otolaryngol Head Neck Surg. 2021 Apr;164(4):733-740
pubmed: 32928026
J Biomed Inform. 2019 Jul;95:103208
pubmed: 31078660
Cancers (Basel). 2021 Apr 07;13(8):
pubmed: 33916999
J Clin Oncol. 2015 Oct 10;33(29):3227-34
pubmed: 26351353
Oral Oncol. 2017 Nov;74:105-110
pubmed: 29103737
Cancer Epidemiol. 2020 Feb;64:101649
pubmed: 31816512
Oral Oncol. 2019 Sep;96:1-6
pubmed: 31422200
Mayo Clin Proc. 2016 Mar;91(3):386-96
pubmed: 26944243
Br J Cancer. 2015 Jun 30;113(1):131-4
pubmed: 26042932